REMOTE ELECTRICAL NEUROMODULATION FOR MIGRAINES (REQUIRES PREAUTHORIZATION)
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Nebraska Policy I.218 alerts
Get alerted when Policy I.218 changes without checking for updates manually.
Monitor payer policy activity
This policy defines medical necessity, coverage criteria, contraindications, and prior authorization requirements for use of remote electrical neuromodulation devices (e.g., Nerivio) for acute and preventive treatment of migraine for BCBS Nebraska members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Remote Electrical Neuromodulation (REN)
Initial Therapy (Adults)
Initiation of Use — REN is medically necessary when ALL of the following are met:
Adult initiation criteria
- Additional criteria (pick one): 1) Insufficient response, contraindication, or intolerance to 2 or more guideline-recommended preventive headache medications (e.g., anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors); OR 2) Pregnancy, breastfeeding, or planning to conceive; OR 3) At risk for or have a history of medication overuse headache; OR 4) At risk for drug-drug interactions with medications for comorbid conditions.
Initial Therapy (Pediatrics, prevention)
Preventive treatment — pediatric preventive coverage when ALL of the following are met:
Clinical input notes first-line use may be recommended in children/adolescents; reduction in school absenteeism may be used to assess benefit.
Continuation Therapy
Continuation of Use — REN continued when ALL of the following are met:
Clinician attestation is acceptable for documenting benefit.
Investigational Use
Nerivio (remote electrical neuromodulation) is contraindicated in patients with uncontrolled epilepsy and in patients with an active implantable medical device such as a pacemaker, hearing aid implant, or any implanted electronic device. The device has not been evaluated in patients with congestive heart failure, severe cardiac or cerebrovascular disease, pregnancy, or in patients under 8 years of age.
These Medical Policies have been developed by the BCBSN Medical Policy Committee to guide determination of scientific validity and to assist in administering plan benefits. The policies are evidence-based and subject to change; they do not constitute authorization, certification, or a contract for benefits. Benefits for a particular service or item are determined by the terms and conditions of the applicable benefit contract, and providers remain responsible for delivering medical advice and treatment.
Use of remote electrical neuromodulation (REN) for prevention or management of migraine that falls outside the policy's specified medical necessity criteria is considered investigational and may be denied. Examples include use in individuals who do not meet the age criteria, those without an ICHD-3 migraine diagnosis, or when the requirement of 6 to 24 headache days per 28-day period in each of the prior 3 months is not met.
Coding and Key Numeric Criteria
| A4540 | Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm |
| affected codes | The policy references CPT codes; specific codes are listed elsewhere in the full policy. |
Provider Requirements and Prior Authorization
Preauthorization required — document age, ICHD‑3 diagnosis, headache frequency
REN (e.g., Nerivio) requires preauthorization. Requests must document medical necessity including that the individual is ≥18 years old, that headaches meet ICHD‑3 diagnostic criteria for migraine, and the frequency of headache days (6 to 24 headache days per 28‑day period in each of the 3 months preceding use).
- Include age (≥18 years).
- Confirm ICHD‑3 migraine diagnosis.
- Provide headache day counts for each of the prior 3 months (6–24 per 28‑day period).
Preauthorization requirement — submit as specified by BCBS‑NE
Remote electrical neuromodulation for migraine requires preauthorization as specified by BCBS‑NE; affected billing codes are referenced elsewhere in the policy and must be included with the authorization request as applicable.
- Follow BCBS‑NE preauthorization procedures and submit any referenced CPT/HCPCS codes (see coding section).
Required prior medication trials (adults) — document ≥2 guideline preventive trials
For adult initiation, include documentation of insufficient response, contraindication, or intolerance to two or more guideline‑recommended preventive headache medications as one pathway to meet the additional criteria for REN.
- Examples of guideline‑recommended preventive medications: anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors.
- Provider must state whether trials were inadequate due to lack of efficacy, contraindication, or intolerance.
Provide complete supporting documentation and clinician attestations
Ensure authorization requests include all required supporting documentation and attestations; clinician attestation of medical necessity and prior treatment history should be provided where applicable.
- Include prior treatment history and reason for REN consideration (e.g., pregnancy, medication overuse risk, drug‑drug interaction risk).
- Provide clinician attestation when documenting clinical benefit for continuation requests.
Required documentation — age, ICHD‑3 confirmation, headache day counts
Required documentation for both initiation and continuation must include the patient’s age, confirmation that headaches meet ICHD‑3 diagnostic criteria, and the count of headache days per 28‑day period for each of the prior 3 months.
- For continuation, also document clinical benefit (examples: improved pain relief, reduced frequency/severity/duration, reduced functional disability, reduced absenteeism, or reduced concomitant medication use).
- Assessment for preventive benefit is reasonable after a minimum of 8–12 weeks.
Committee reviews scientific publications to develop evidence‑based policies
The BCBS‑NE Medical Policy Committee reviews scientific publications to develop evidence‑based policies; providers should recognize policies are based on those reviews and continue to provide individualized medical care.
- The Committee reviews peer‑reviewed journals and new technologies on a regular basis to inform policies.
Coverage outside criteria is investigational — risk of denial
Use of REN outside the specified medical necessity criteria (age, ICHD‑3 migraine diagnosis, 6–24 headache days per 28‑day period in each of the prior 3 months, or the listed additional indications) is considered investigational and may be denied.
- Do not request coverage for indications outside the policy criteria without supporting evidence; such requests are subject to denial.
Policy administrative disclaimer — policies used to administer benefits, not a benefit guarantee
These Medical Policies are used to administer plan benefits and do not constitute authorization, certification, or a contract for benefits; coverage for a specific service is determined by the member’s benefit contract.
- Providers remain responsible for providing medical advice and treatment regardless of policy determinations.
Background
Migraine is a common neurologic disorder with episodic and chronic presentations defined by headache frequency. Remote electrical neuromodulation (REN) devices such as Nerivio are nonpharmacologic, wearable stimulators applied to the upper arm that activate peripheral nerves to induce conditioned pain modulation. REN may be used acutely at migraine onset and can also be used every-other-day for preventive treatment. Clinical use aims to reduce headache frequency and severity, improve function (for example, reduce work or school absenteeism), and decrease use of acute headache medications.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.